Publications by authors named "Pooria Torkaman"
Int Immunopharmacol
October 2021
Article Synopsis
- The study investigates the potential of adalimumab, a TNF-α blocker, as a treatment for severe COVID-19 when combined with remdesivir and dexamethasone.
- A randomized controlled trial included 68 patients, with 34 receiving adalimumab and 34 in the control group, both groups getting remdesivir and dexamethasone.
- Results showed no significant differences in mortality, mechanical ventilation needs, or hospitalization duration between the two groups, indicating adalimumab may not be effective for severe COVID-19 cases.
